In a report published Monday, Citigroup analyst Garen Sarafian initiated coverage on PRA Health Sciences (NASDAQ: PRAH) with a Neutral rating and $24.00 price target.
In the report, Citigroup noted, “We are initiating on PRA Health Sciences...
The Prudential Regulation Authority (PRA) has today published a consultation paper introducing a new accountability regime for the insurance sector. The proposals aim to embed a clearer system of accountability and responsibility for senior...
PRA Health Sciences and INC Research have both seen their shares tick upward since pulling off IPOs earlier this month, a sign that, despite biotech's boom and bust, the window for CRO debuts remains open.
WASHINGTON (dpa-AFX) - Clinical research company PRA Health Sciences Inc
(PRAH) Tuesday announced the closing of its initial public offering of its
common stock. Shares of PRA began trading on the Nasdaq Global Select Market on
November 13 under...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Pro-Assurance (PRA):